Love Hemp Group PLC (AQSE:LIFE) (OTCQB:WRHLF), is pleased to announce that all resolutions were duly passed at the General Meeting of the Company held today

Accordingly, as per the announcement of 19 February 2021, a total of 86,096,355 ordinary shares of 1p each in the Company “(Ordinary Shares”) will be allotted at a price of 2.5p per share in relation to the conversion of Convertible Debentures and in exchange for debt.


In addition, the Company has also issued a further 229,415 Ordinary Shares at a price of 2.5p per share for the settlement of fees in lieu of cash.

Application will be made for the 86,325,770 new Ordinary Shares to be admitted to trading on the AQSE Growth Market and admission is expected to become effective, and dealings in the new Ordinary Shares are expected to commence, on 16 March 2021.

Following this issue, the Company’s has 487,766,189 Ordinary Shares in issue, each share carrying the right to one vote. The figure of 487,766,189 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.

Andrew Male, Chairman and Director of Love Hemp Group, says “With the conversion of the Convertible Debentures that were originally used to finance the Company and the settlement of other liabilities through share issues, we have now eliminated approximately £4.5m in debt.

“This action positions the Group with little to no debt and effectively concludes the housekeeping actions we embarked on some 3 months ago. The change of name to Love Hemp Group plc has helped align the listed company with our operational entity and we look forward to building the brand, product line and overall business going forward in support of Tony Calamita, CEO of Love Hemp Group and co-founder of Love Hemp Ltd.”

About Love Hemp
Love Hemp is one of the UK’s leading CBD and Hemp product suppliers and has more than 40 product lines, comprising oils, sprays and vapes and a variety of edible and water-based CBD products. Love Hemp has established relationships with over 2,000 stores in the UK, including leading brands such as Sainsbury’s, Boots, Ocado and Holland & Barrett.

Love Hemp is positioned to take advantage of the huge opportunities available in the UK and European legal cannabis space, which is set to be the largest in the world within five years.

For further information please contact:

Andrew Male
Chairman & Director
+44 (0) 7926 397 675
andrew@worldhighlife.uk

AQSE Corporate Adviser
Mark Anwyl/Allie Feuerlein
Peterhouse Capital Limited
+44 (0) 20 7469 0930
ma@peterhousecap.com
af@peterhousecap.com

Financial PR
Tim Blythe
Alice McLaren
Madeleine Gordon-Foxwell
+44 (0) 207 318 3205
lovehemp@blytheweigh.com

Financial Advisor
Rupert Fane
H&P Advisory Limited
+44 (0) 20 7907 8500
rf@hannam.partners

For more information on World High Life please visit: www.worldhighlife.uk
www.lovehempgroup.com

Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Love Hemp Group PLC

View source version on accesswire.com:
https://www.accesswire.com/635015/Love-Hemp-Group-PLC-Announces-Result-of-General-Meeting

News Provided by ACCESSWIRE via QuoteMedia

Two US-based multi-state operators (MSOs) added fuel to the ongoing merger and acquisition (M&A) train currently making its way across the cannabis sector.

On the flip side, one of Canada’s biggest cannabis producers told the market this week that it has no interest in further acquisitions in the Canadian market.

Keep reading... Show less

 Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”), a wellness company that makes and sells plant-based products, is ramping up production at its Victoria, BC production facility to fulfill incoming orders from seven Whole Foods Market in Ontario, Canada (“Whole Foods”).

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/84022_947985ee845d7afb_001.jpg

Keep reading... Show less
  • Domestic Medical Net Revenue Steady at $26.9 Million
  • Strong International Medical Net Revenue of $9.4 Million
  • Total Cannabis Net Revenue, Excluding Provisions, of $58.4 Million
  • Business Transformation Plan Continues, Management Expects to Deliver Incremental Cost-Saving Measures of $60 Million to $80 Million Annually
  • Balance Sheet Remains Strong with ~$525 Million of Cash on Hand at May 12, 2021
  • Lead Independent Director Ronald Funk Appointed as Chairman, Michael Singer to Remain Board Member

NYSE | TSX: ACB

 Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced its financial and operational results for the third quarter of fiscal 2021 ended March 31, 2021 .

Keep reading... Show less

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies

Keep reading... Show less

Experienced executives fill senior roles in business development, M&A, clinic operations and design, and corporate communications

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the appointments of five experienced leaders to support strategic growth initiatives across the Company’s three divisions Numinus Health, Numinus R&D and Numinus Bioscience.

Keep reading... Show less